A Randomized, Multi-center, Single Dose, Cross over Study Comparing the Pharmacokinetic of Bio-similar EPTACOG Alfa with NOVOSEVEN®, in Patients with Congenital Factor VII Deficiency
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2018
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Factor-VII-Deficiency
- Focus Pharmacokinetics
- Sponsors AryoGen Pharmed
- 13 Dec 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Feb 2018.
- 23 Sep 2017 Recruitment is completed.
- 15 Feb 2017 New trial record